FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
RegulatoryapprovedFayuviPositive
AI Analysis
Summary
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), the first gene therapy treatment for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), a rare genetic disorder.
Outcome Details
FDA approval for first gene therapy treatment for pediatric MPS IIIA (Sanfilippo syndrome type A)
Importance:9/10
Sentiment:
0.95
FDA ApprovalGene TherapyRare DiseasePediatricFirst-in-ClassSanfilippo SyndromeMPS IIIA
Related Companies
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 17, 2026 6:31 PM